Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients

Journal of Neural Transmission

Volumn 108, Issue 2, 2001, Pages 231-246

  Rosler N ^a   Wichart, I ^a   Jellinger, K A ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

protein; Alzheimer's disease; Amyloid peptide; Apolipoprotein E; Cerebrospinal fluid; Interleukin 6; Neurochemical profiles; Substance P

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; INTERLEUKIN 6; SUBSTANCE P; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; NEUROCHEMISTRY; ONSET AGE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE P; TAU PROTEINS;

EID: 0034942145     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170091     Document Type: Article

References (83)

1. (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
2. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
3. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
4. Biological markers for the diagnosis of Alzheimer's disease
5. 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
6. The genetics of Alzheimer's disease - Current status and future prospects
7. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing
8. Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type
9. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
10. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
11. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6
12. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid
13. The role of apoe polymorphisms in late-onset dementias
14. Somatostatin-like immunoreactivity and substance P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus
15. The pathogenesis of senile plaques
16. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type
17. "Mini mental state": A practical method for grading the cognitive state of patients for the clinician
18. On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases
19. Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG
20. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease
21. Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequeli
22. Cerebrospinal fluid levels of Aβ42 and tau: Potential markers of Alzheimer's disease
23. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
24. Interleukin-6 secretion from human astrocytoma cells induced by substance P
25. Tau protein and the neurofibrillary pathology of Alzheimer's disease
26. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
27. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease - A comparative review
28. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls
29. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons
30. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease
31. Oligoclonal bands and blood-cerebrospinal fluid barrier dysfunction in a subset of patients with Alzheimer disease: Comparison with vascular dementia, major depression, and multiple sclerosis
32. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
33. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - Correlation with degree of cognitive impairment
34. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
35. (1-42) and tau levels in CSF
36. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
37. The neuropathological diagnosis of Alzheimer disease
38. What is new in degenerative dementia disorders?
39. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
40. (1-42)(43) in Alzheimer's disease: A study in Japan
41. CSF and serum concentrations of albumin and IgG in Alzheimer's disease
42. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P
43. 1-antichymotrypsin
44. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease
45. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid
46. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein
47. Substance P and neuropsychiatric disorders: An overview
48. 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type
49. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
50. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease
51. Neuroimmune mechanisms in Alzheimer disease pathogenesis
52. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
53. Blood-brain-barrier in a geriatric population: Barrier function in degenerative and vascular dementias
54. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease
55. 42 in the cerebrospinal fluid of patients with Alzheimer's disease
56. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols
57. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
58. Serum levels of interleukin-6 and acute phase response
59. Cerebrospinal fluid concentrations of soluble amyloid β-protein and apolipoprotein E in patients with Alzheimer's disease: Correlations with amyloid load in the brain
60. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
61. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system
62. Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease
63. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease
64. CSF β-amyloid, cognition, and ApoE genotype in Alzheimer's disease
65. (1-42)(43) as a biochemical marker of Alzheimer's disease
66. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects
67. A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia
68. Central nervous system IgG synthesis rates in Alzheimer disease: Possible differences in early-onset and late-onset subgroups
69. Molecular genetics of Alzheimer's disease
70. Longitudinal stability of CSF tau in Alzheimer patients
71. Three-year-follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
72. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type
73. Neuropeptide changes in dementia: Pathogenic implications and diagnostic value
74. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive enzyme-linked immunosorbent assay
75. Concentrations of amyloid-β-protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease
76. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
77. Apolipoprotein E: Binding to soluble Alzheimer's β-amyloid
78. 2-macroglobulin and C-reactive protein
79. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia
80. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides